Cargando…
Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer’s disease-associated biomarkers alterations among de novo Parkinson’s disease patients: a prospective cohort study
BACKGROUND: Dementia is a prevalent non-motor manifestation among individuals with advanced Parkinson’s disease (PD). Glial fibrillary acidic protein (GFAP) is an inflammatory marker derived from astrocytes. Research has demonstrated the potential of plasma GFAP to forecast the progression to dement...
Autores principales: | Liu, Tingting, Zuo, Hongzhou, Ma, Di, Song, Dan, Zhao, Yuying, Cheng, Oumei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357612/ https://www.ncbi.nlm.nih.gov/pubmed/37475029 http://dx.doi.org/10.1186/s12974-023-02843-5 |
Ejemplares similares
-
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
por: Irwin, David J., et al.
Publicado: (2020) -
Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease
por: Sweeney, Melanie D, et al.
Publicado: (2015) -
Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease
por: Alexopoulos, Panagiotis, et al.
Publicado: (2016) -
Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia
por: Forlenza, Orestes V., et al.
Publicado: (2015) -
Plasma GFAP in Parkinson’s disease with cognitive impairment and its potential to predict conversion to dementia
por: Tang, Yilin, et al.
Publicado: (2023)